6990 Share Price Performance
HK$477.80
175.40 (58.00%)
10.5% undervalued intrinsic discount
HK$533.85
Fair Value
Price HK$477.80
AnalystConsensusTarget HK$533.85
Fair ValueHK$533.85
Share Pricen/a
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
6990 Community Narratives
AN
Fair Value
·Fair Value HK$533.85 10.5% undervalued intrinsic discount
ADC Expansion And Global Partnerships Will Shape This Biopharma’s Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ADC Expansion And Global Partnerships Will Shape This Biopharma’s Long Term Outlook
Catalysts About Sichuan Kelun-Biotech Biopharmaceutical Sichuan Kelun-Biotech Biopharmaceutical focuses on the R&D, manufacturing and commercialization of drugs for oncology, immunology and metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
HK$533.85
10.5% undervalued intrinsic discount
Fair Value
Profit Margin
23.49%
Future PE
82.72x
Price in 2029
HK$658.39
Trending Discussion
Recently Updated Narratives
AN
ADC Expansion And Global Partnerships Will Shape This Biopharma’s Long Term Outlook
Fair Value: HK$533.85 10.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Key Details
About 6990
- Founded
- 2016
- Employees
- 2045
- CEO
- WebsiteView website
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
